Overview

A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC).

Status:
Recruiting

Trial end date:
2022-05-01

Target enrollment:

Participant gender:

Summary

The study primary objective is to evaluate the effect of HC-1119 soft capsules versus placebo on overall survival (OS) in mCRPC patients who have failed or become intolerant to the treatments with both abiraterone acetate and docetaxel, or who are not suitable for docetaxel treatment.

Phase:

Phase 3

Details

Lead Sponsor:

Hinova Pharmaceuticals Inc.
Sichuan Haisco Pharmaceutical Group Co., Ltd.